Barriers to Use of Palliative Care and Advance Care Planning Discussions for Patients With End-Stage Liver Disease.
death
decompensated cirrhosis
quality of life
supportive care
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
03
10
2018
revised:
28
02
2019
accepted:
10
03
2019
pubmed:
20
3
2019
medline:
15
12
2020
entrez:
20
3
2019
Statut:
ppublish
Résumé
Despite evidence for the benefits of palliative care (PC) referrals and early advance care planning (ACP) discussions for patients with chronic diseases, patients with end-stage liver disease (ESLD) often do not receive such care. We sought to examine physicians' perceptions of the barriers to PC and timely ACP discussions for patients with ESLD. We conducted a cross-sectional survey of hepatologists and gastroenterologists who provide care to adult patients with ESLD, recruited from the American Association for the Study of Liver Diseases 2018 membership registry. Using a questionnaire adapted from prior studies, we assessed physicians' perceptions of barriers to PC use and timely ACP discussions; 396 of 1236 eligible physicians (32%) completed the questionnaire. The most commonly cited barriers to PC use were cultural factors that affect perception of PC (by 95% of respondents), unrealistic expectations from patients about their prognosis (by 93% of respondents), and competing demands for clinicians' time (by 91% of respondents). Most respondents (81%) thought that ACP discussions with patients who have ESLD typically occur too late in the course of illness. The most commonly cited barriers to timely ACP discussions were insufficient communication between clinicians and families about goals of care (by 84% of respondents) and insufficient cultural competency training about end-of-life care (81%). There are substantial barriers to use of PC and timely discussions about ACP-most hepatologists and gastroenterologists believe that ACP occurs too late for patients with ESLD. Strategies are needed to overcome barriers and increase delivery of high-quality palliative and end-of-life care to patients with ESLD.
Sections du résumé
BACKGROUND & AIMS
Despite evidence for the benefits of palliative care (PC) referrals and early advance care planning (ACP) discussions for patients with chronic diseases, patients with end-stage liver disease (ESLD) often do not receive such care. We sought to examine physicians' perceptions of the barriers to PC and timely ACP discussions for patients with ESLD.
METHODS
We conducted a cross-sectional survey of hepatologists and gastroenterologists who provide care to adult patients with ESLD, recruited from the American Association for the Study of Liver Diseases 2018 membership registry. Using a questionnaire adapted from prior studies, we assessed physicians' perceptions of barriers to PC use and timely ACP discussions; 396 of 1236 eligible physicians (32%) completed the questionnaire.
RESULTS
The most commonly cited barriers to PC use were cultural factors that affect perception of PC (by 95% of respondents), unrealistic expectations from patients about their prognosis (by 93% of respondents), and competing demands for clinicians' time (by 91% of respondents). Most respondents (81%) thought that ACP discussions with patients who have ESLD typically occur too late in the course of illness. The most commonly cited barriers to timely ACP discussions were insufficient communication between clinicians and families about goals of care (by 84% of respondents) and insufficient cultural competency training about end-of-life care (81%).
CONCLUSION
There are substantial barriers to use of PC and timely discussions about ACP-most hepatologists and gastroenterologists believe that ACP occurs too late for patients with ESLD. Strategies are needed to overcome barriers and increase delivery of high-quality palliative and end-of-life care to patients with ESLD.
Identifiants
pubmed: 30885884
pii: S1542-3565(19)30286-1
doi: 10.1016/j.cgh.2019.03.022
pmc: PMC6745282
mid: NIHMS1524097
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2592-2599Subventions
Organisme : NCI NIH HHS
ID : K12 CA087723
Pays : United States
Organisme : NIDDK NIH HHS
ID : K24 DK078772
Pays : United States
Informations de copyright
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1612-1619.e4
pubmed: 28179192
Liver Int. 2018 May;38(5):768-775
pubmed: 29112338
JAMA. 2015 Oct 20;314(15):1565-6
pubmed: 26334719
J Am Geriatr Soc. 2007 Feb;55(2):189-94
pubmed: 17302654
J Clin Oncol. 2016 Sep 10;34(26):3126-32
pubmed: 27400944
J Pain Symptom Manage. 2010 Dec;40(6):899-911
pubmed: 21145468
Crit Care Med. 2006 Oct;34(10):2547-53
pubmed: 16932230
BMJ Open. 2015 Nov 19;5(11):e009241
pubmed: 26586325
BMJ Support Palliat Care. 2016 Mar;6(1):66-74
pubmed: 24916198
JAMA. 2016 Nov 22;316(20):2094-2103
pubmed: 27893130
Chest. 2013 Mar;143(3):736-743
pubmed: 22922517
J Hepatol. 2006 Jan;44(1):217-31
pubmed: 16298014
Dig Dis Sci. 2017 Jan;62(1):84-92
pubmed: 27804005
N Engl J Med. 2010 Aug 19;363(8):733-42
pubmed: 20818875
BMJ. 2010 Mar 23;340:c1345
pubmed: 20332506
JAMA Intern Med. 2015 May;175(5):840-1
pubmed: 25730201
Pediatrics. 2012 Apr;129(4):e975-82
pubmed: 22392177
JAMA Intern Med. 2016 Feb;176(2):263-5
pubmed: 26720644
Oncologist. 2015 Nov;20(11):1326-32
pubmed: 26417037
World J Transplant. 2016 Sep 24;6(3):594-8
pubmed: 27683638
JAMA Intern Med. 2013 Feb 25;173(4):283-90
pubmed: 23358690
Cancer. 2009 May 1;115(9):2013-21
pubmed: 19235253
CMAJ. 2016 Jul 12;188(10):E217-E227
pubmed: 27091801
Hepatology. 2018 May;67(5):2025-2040
pubmed: 29251778
Psychooncology. 2013 Apr;22(4):940-6
pubmed: 22451082
Clin Gastroenterol Hepatol. 2014 Apr;12(4):692-8
pubmed: 23978345
Hepatology. 2017 Nov;66(5):1585-1591
pubmed: 28660622
Cancer. 2003 Dec 1;98(11):2502-10
pubmed: 14635087
Frontline Gastroenterol. 2016 Jan;7(1):4-9
pubmed: 28839829